Jacob T Heggestad, David S Kinnamon, Lyra B Olson, Jason Liu, Garrett Kelly, Simone A Wall, Solomon Oshabaheebwa, Zachary Quinn, Cassio M Fontes, Daniel Y Joh, Angus M Hucknall, Carl Pieper, Jack G Anderson, Ibtehaj A Naqvi, Lingye Chen, Loretta G Que, Thomas Oguin, Smita K Nair, Bruce A Sullenger, Christopher W Woods, Thomas W Burke, Gregory D Sempowski, Bryan D Kraft, Ashutosh Chilkoti
Highly sensitive, specific, and point-of-care (POC) serological assays are an essential tool to manage coronavirus disease 2019 (COVID-19). Here, we report on a microfluidic POC test that can profile the antibody response against multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens-spike S1 (S1), nucleocapsid (N), and the receptor binding domain (RBD)-simultaneously from 60 μl of blood, plasma, or serum. We assessed the levels of antibodies in plasma samples from 31 individuals (with longitudinal sampling) with severe COVID-19, 41 healthy individuals, and 18 individuals with seasonal coronavirus infections...
June 2021: Science Advances